查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298369

抗肥胖藥物市場：按藥物類型、作用機制、給藥途徑、分銷渠道：2023-2032年全球市場機會分析和行業預測

Anti-Obesity Drugs Market By Drug Type, By Mechanism of Action, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 447 Pages | 商品交期: 2-3個工作天內

價格

預計2022年抗肥胖藥物市場價值為16.0536億美元，2032年將達到44.3934億美元，2023年至2032年復合年增長率為10.7%。

肥胖是一種體內脂肪積累過多而對健康產生不利影響的疾病。肥胖通常被定義為體重指數 (BMI) 為 30 或更高。它被廣泛認為是發達國家和發展中國家最大且增長最快的公共衛生問題。抗肥胖藥物是為幫助超重人士而開的藥物。這些藥物通過抑制食慾、增加新陳代謝和阻止食物中脂肪的吸收來發揮作用。常用的抗肥胖藥物包括芬特明、西布曲明、奧利司他和利拉魯□。

Anti-Obesity Drugs Market-IMG1

推動抗肥胖藥物市場增長的主要因素是肥胖患病率的顯著上升、與超重或肥胖相關的健康風險激增以及潛在藥物分子研發活動的增加。例如，Novo Nordisk於2021年6月宣布，美國食品藥品監督管理局（FDA）在美國批准Wegobee，一種每週一次的索馬魯□2.4mg注射液，用於長期體重管理。此外，政府加大努力讓人們意識到與肥胖相關的健康問題，以及政府和私人實體增加大規模生產抗肥胖藥物的資金是推動市場增長的關鍵市場。為玩家帶來新的市場可能性。

然而，嚴格的藥物審批政策和替代療法的可用性阻礙了市場的增長。相反，肥胖和 2 型糖尿病的患病率不斷上升，促使市場研究人員和供應商研究能夠同時對抗肥胖和 2 型糖尿病的藥物。因此，肥胖人口的增加、不健康的飲食習慣和久坐的生活方式的增加可能會為抗肥胖藥物開闢新的市場潛力，為預測期內的市場增長提供利潤豐厚的機會。

2021年，北美將佔據抗肥胖藥物市場的大部分份額，並預計在預測期內保持其主導地位。抗肥胖藥物市場主要是由肥胖人數的增加和抗肥胖藥物的高醫療保健支出推動的。此外，由於公眾對與肥胖相關的嚴重慢性疾病的認識提高以及主要市場進入者對研發活動的投資增加，臨床試驗數量激增預計將推動市場增長。

由於醫療保健支出增加以及主要市場進入者針對肥胖治療新藥開發的研發活動激增，預計亞太地區在預測期內將實現最快的複合年增長率。此外，印度、中國和韓國等新興國家肥胖患病率不斷上升，人們對抗肥胖藥物的認識不斷增強，也促進了該地區抗肥胖藥物市場的增長。

然而，由於肥胖患病率上升，預計市場將在大流行後復蘇。此外，大流行期間不健康和久坐的生活方式的增加預計也將刺激市場增長。

目錄

第 1 章 簡介

第二章執行摘要

第三章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
    • 供應商的議價能力
    • 買方議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 促進者
      • 肥胖症患病率增加
      • 管道藥物數量增加
      • 臨床試驗數量增加
    • 阻礙因素
      • 抗肥胖藥物的潛在副作用
    • 機會
      • 新興經濟體的高增長潛力
  • COVID-19 市場影響分析

4. 肥胖藥物市場（按藥物類型）

  • 概述
    • 市場規模和預測
  • 處方藥
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 非處方藥物
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

5 抗肥胖藥物市場（按作用機制）

  • 概述
    • 市場規模和預測
  • 中樞作用抗肥胖藥
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家分類
  • 外周抗肥胖藥
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

6 抗肥胖藥物市場（按給藥途徑）

  • 概述
    • 市場規模和預測
  • 口服給藥途徑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 皮下途徑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

7.抗肥胖藥物市場，按分銷渠道

  • 概述
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 零售藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類
  • 網上藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場份額分析：按國家分類

8.按地區劃分的抗肥胖藥物市場

  • 概述
    • 市場規模/預測：按地區
  • 北美
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按作用機制
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按作用機制
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按作用機制
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 亞太其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按作用機制
    • 市場規模和預測：按管理途徑
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分
      • 其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按作用機制
      • 市場規模和預測：按管理途徑
      • 市場規模和預測：按分銷渠道劃分

第9章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10大公司產品圖
  • 比賽儀表板
  • 比賽熱圖
  • 2022 年頂級公司定位

第十章公司簡介

  • Currax Pharmaceuticals LLC
  • KVK Tech Inc.
  • Gelesis Holdings, INC.
  • Vivus LLC.
  • CHEPLAPHARM Arzneimittel GmbH
  • Pfizer Inc.
  • Rhythm Pharmaceuticals
  • Novo Nordisk A/S
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
Product Code: A03823

The anti-obesity drugs market valued for $1,605.36 million in 2022 and is estimated to reach $4,439.34 million by 2032, exhibiting a CAGR of 10.7% from 2023 to 2032. Obesity is a medical condition in which excess body fat is accumulated to an extent that it causes a negative effect on health. It is generally defined as having a body mass index (BMI) of 30 or greater. It is widely recognized as the largest and fastest-growing public health problem in developed and developing countries. Anti-obesity drugs are medications prescribed to help people who are overweight. These drugs work by suppressing appetite, increasing metabolism, or blocking the absorption of fat from food. Some of the commonly prescribed anti-obesity drugs include phentermine, sibutramine, orlistat, and liraglutide.

Anti-Obesity Drugs Market - IMG1

The key factor that drives the growth of the anti-obesity drugs market is significant rise in the prevalence rate of obesity, surge in health risks associated with being overweight or obese and increase in number of research and development activities on several potential drug molecules that target both obesity and type 2 diabetes mellitus. For instance, in June 2021 Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Wegovy for once weekly semaglutide 2.4 mg injection in the U.S. for chronic weight management. Furthermore, increase in number of initiatives taken by government to make people aware about health-related issues with obesity and rise in funding from government and private bodies for large-scale production of anti-obesity drugs, may open up new market potential for key market players that drive the growth of the market.

However, stringent drug approval policies and the availability of alternative therapies hamper market growth. Conversely, rise in the prevalence of obesity and type 2 diabetes is encouraging researchers and vendors in the market to research drugs that can counter both obesity and type 2 diabetes. Hence, increase in obese population, rise in unhealthy eating habits, and sedentary lifestyles may open up new market potentials for anti-obesity drugs and are expected to provide lucrative opportunity for the growth of the market during the forecast period.

North America accounted for a majority of the anti-obesity drug market share in 2021 and is anticipated to remain dominant during the forecast period. The anti-obesity drugs market is mainly driven by the increase in obese population and high healthcare expenditure on anti-obesity drugs. Furthermore, increase in awareness among the population regarding severe chronic diseases related to obesity and surge in number of clinical trials owing to a rise in investment by key market players in R&D activities are expected to fuel the market growth.

Asia-Pacific is expected to register the fastest CAGR during the forecast period owing to increase in healthcare expenditure and surge in R&D activities by key market players for the development of new drugs to treat obesity in the Asia-Pacific region. Furthermore, the increase in prevalence of obesity and rise in awareness about anti-obesity drugs in developing countries such as India, China, and South Korea contribute toward the growth of the anti-obesity drug market in this region.

However, the market is expected to witness a recovery post pandemic owing to rise in prevalence of obesity. In addition, an increase in number of people adopting unhealthy and sedentary lifestyles during the pandemic is anticipated to fuel the growth of the market.

The anti-obesity drugs market is segmented on the basis of drug type, mechanism of action, route of administration, distribution channel, and region. By drug type, the market is bifurcated into prescription drugs, and over the counter drugs. By mechanism of action, the market is divided into centrally acting anti-obesity drugs and peripherally acting anti-obesity drugs. By route of administration, the market is categorized into oral route and subcutaneous route. By distribution channel, the market is classified into hospital pharmacies, retail pharmacies and online pharmacies. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in the anti-obesity drugs market are: Currax Pharmaceuticals LLC, Pfizer Inc, Novo Nordisk A/S, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, KVK Tech Inc, CHEPLAPHARM Arzneimittel GmbH, Gelesis Holdings, INC., VIVUS LLC, and Rhythm Pharmaceuticals.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the anti-obesity drugs market analysis from 2022 to 2032 to identify the prevailing anti-obesity drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the anti-obesity drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as anti-obesity drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Prescription Drugs
  • Over The Counter Drugs

By Mechanism of Action

  • Centrally Acting Anti-Obesity Drugs
  • Peripherally Acting Anti-Obesity Drugs

By Route of Administration

  • Oral Route
  • Subcutaneous Route

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

  • Pfizer Inc.
  • Novo Nordisk A/S
  • Boehringer Ingelheim International GmbH
  • KVK Tech Inc.
  • Gelesis Holdings, INC.
  • Vivus LLC.
  • Currax Pharmaceuticals LLC
  • GlaxoSmithKline plc
  • CHEPLAPHARM Arzneimittel GmbH
  • Rhythm Pharmaceuticals

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in the prevalence of obesity
      • 3.4.1.2. Increase in number of drugs in pipeline
      • 3.4.1.3. Increase in number of clinical trials
    • 3.4.2. Restraints
      • 3.4.2.1. Potential side effects of anti-obesity drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in developing economies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Prescription Drugs
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Over The Counter Drugs
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Centrally Acting Anti-Obesity Drugs
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Peripherally Acting Anti-Obesity Drugs
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Oral Route
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Subcutaneous Route
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Retail Pharmacies
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Online Pharmacies
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: ANTI-OBESITY DRUGS MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key trends and opportunities
    • 8.2.2. Market size and forecast, by Drug Type
    • 8.2.3. Market size and forecast, by Mechanism of Action
    • 8.2.4. Market size and forecast, by Route of Administration
    • 8.2.5. Market size and forecast, by Distribution Channel
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Key market trends, growth factors and opportunities
      • 8.2.6.1.2. Market size and forecast, by Drug Type
      • 8.2.6.1.3. Market size and forecast, by Mechanism of Action
      • 8.2.6.1.4. Market size and forecast, by Route of Administration
      • 8.2.6.1.5. Market size and forecast, by Distribution Channel
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Key market trends, growth factors and opportunities
      • 8.2.6.2.2. Market size and forecast, by Drug Type
      • 8.2.6.2.3. Market size and forecast, by Mechanism of Action
      • 8.2.6.2.4. Market size and forecast, by Route of Administration
      • 8.2.6.2.5. Market size and forecast, by Distribution Channel
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Key market trends, growth factors and opportunities
      • 8.2.6.3.2. Market size and forecast, by Drug Type
      • 8.2.6.3.3. Market size and forecast, by Mechanism of Action
      • 8.2.6.3.4. Market size and forecast, by Route of Administration
      • 8.2.6.3.5. Market size and forecast, by Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key trends and opportunities
    • 8.3.2. Market size and forecast, by Drug Type
    • 8.3.3. Market size and forecast, by Mechanism of Action
    • 8.3.4. Market size and forecast, by Route of Administration
    • 8.3.5. Market size and forecast, by Distribution Channel
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Key market trends, growth factors and opportunities
      • 8.3.6.1.2. Market size and forecast, by Drug Type
      • 8.3.6.1.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.1.4. Market size and forecast, by Route of Administration
      • 8.3.6.1.5. Market size and forecast, by Distribution Channel
      • 8.3.6.2. France
      • 8.3.6.2.1. Key market trends, growth factors and opportunities
      • 8.3.6.2.2. Market size and forecast, by Drug Type
      • 8.3.6.2.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.2.4. Market size and forecast, by Route of Administration
      • 8.3.6.2.5. Market size and forecast, by Distribution Channel
      • 8.3.6.3. UK
      • 8.3.6.3.1. Key market trends, growth factors and opportunities
      • 8.3.6.3.2. Market size and forecast, by Drug Type
      • 8.3.6.3.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.3.4. Market size and forecast, by Route of Administration
      • 8.3.6.3.5. Market size and forecast, by Distribution Channel
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Key market trends, growth factors and opportunities
      • 8.3.6.4.2. Market size and forecast, by Drug Type
      • 8.3.6.4.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.4.4. Market size and forecast, by Route of Administration
      • 8.3.6.4.5. Market size and forecast, by Distribution Channel
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Key market trends, growth factors and opportunities
      • 8.3.6.5.2. Market size and forecast, by Drug Type
      • 8.3.6.5.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.5.4. Market size and forecast, by Route of Administration
      • 8.3.6.5.5. Market size and forecast, by Distribution Channel
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Key market trends, growth factors and opportunities
      • 8.3.6.6.2. Market size and forecast, by Drug Type
      • 8.3.6.6.3. Market size and forecast, by Mechanism of Action
      • 8.3.6.6.4. Market size and forecast, by Route of Administration
      • 8.3.6.6.5. Market size and forecast, by Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key trends and opportunities
    • 8.4.2. Market size and forecast, by Drug Type
    • 8.4.3. Market size and forecast, by Mechanism of Action
    • 8.4.4. Market size and forecast, by Route of Administration
    • 8.4.5. Market size and forecast, by Distribution Channel
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Key market trends, growth factors and opportunities
      • 8.4.6.1.2. Market size and forecast, by Drug Type
      • 8.4.6.1.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.1.4. Market size and forecast, by Route of Administration
      • 8.4.6.1.5. Market size and forecast, by Distribution Channel
      • 8.4.6.2. China
      • 8.4.6.2.1. Key market trends, growth factors and opportunities
      • 8.4.6.2.2. Market size and forecast, by Drug Type
      • 8.4.6.2.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.2.4. Market size and forecast, by Route of Administration
      • 8.4.6.2.5. Market size and forecast, by Distribution Channel
      • 8.4.6.3. Australia
      • 8.4.6.3.1. Key market trends, growth factors and opportunities
      • 8.4.6.3.2. Market size and forecast, by Drug Type
      • 8.4.6.3.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.3.4. Market size and forecast, by Route of Administration
      • 8.4.6.3.5. Market size and forecast, by Distribution Channel
      • 8.4.6.4. India
      • 8.4.6.4.1. Key market trends, growth factors and opportunities
      • 8.4.6.4.2. Market size and forecast, by Drug Type
      • 8.4.6.4.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.4.4. Market size and forecast, by Route of Administration
      • 8.4.6.4.5. Market size and forecast, by Distribution Channel
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Key market trends, growth factors and opportunities
      • 8.4.6.5.2. Market size and forecast, by Drug Type
      • 8.4.6.5.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.5.4. Market size and forecast, by Route of Administration
      • 8.4.6.5.5. Market size and forecast, by Distribution Channel
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Key market trends, growth factors and opportunities
      • 8.4.6.6.2. Market size and forecast, by Drug Type
      • 8.4.6.6.3. Market size and forecast, by Mechanism of Action
      • 8.4.6.6.4. Market size and forecast, by Route of Administration
      • 8.4.6.6.5. Market size and forecast, by Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key trends and opportunities
    • 8.5.2. Market size and forecast, by Drug Type
    • 8.5.3. Market size and forecast, by Mechanism of Action
    • 8.5.4. Market size and forecast, by Route of Administration
    • 8.5.5. Market size and forecast, by Distribution Channel
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Key market trends, growth factors and opportunities
      • 8.5.6.1.2. Market size and forecast, by Drug Type
      • 8.5.6.1.3. Market size and forecast, by Mechanism of Action
      • 8.5.6.1.4. Market size and forecast, by Route of Administration
      • 8.5.6.1.5. Market size and forecast, by Distribution Channel
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Key market trends, growth factors and opportunities
      • 8.5.6.2.2. Market size and forecast, by Drug Type
      • 8.5.6.2.3. Market size and forecast, by Mechanism of Action
      • 8.5.6.2.4. Market size and forecast, by Route of Administration
      • 8.5.6.2.5. Market size and forecast, by Distribution Channel
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Key market trends, growth factors and opportunities
      • 8.5.6.3.2. Market size and forecast, by Drug Type
      • 8.5.6.3.3. Market size and forecast, by Mechanism of Action
      • 8.5.6.3.4. Market size and forecast, by Route of Administration
      • 8.5.6.3.5. Market size and forecast, by Distribution Channel
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Key market trends, growth factors and opportunities
      • 8.5.6.4.2. Market size and forecast, by Drug Type
      • 8.5.6.4.3. Market size and forecast, by Mechanism of Action
      • 8.5.6.4.4. Market size and forecast, by Route of Administration
      • 8.5.6.4.5. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Currax Pharmaceuticals LLC
    • 10.1.1. Company overview
    • 10.1.2. Key Executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Key strategic moves and developments
  • 10.2. KVK Tech Inc.
    • 10.2.1. Company overview
    • 10.2.2. Key Executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
  • 10.3. Gelesis Holdings, INC.
    • 10.3.1. Company overview
    • 10.3.2. Key Executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
    • 10.3.7. Key strategic moves and developments
  • 10.4. Vivus LLC.
    • 10.4.1. Company overview
    • 10.4.2. Key Executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Key strategic moves and developments
  • 10.5. CHEPLAPHARM Arzneimittel GmbH
    • 10.5.1. Company overview
    • 10.5.2. Key Executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
  • 10.6. Pfizer Inc.
    • 10.6.1. Company overview
    • 10.6.2. Key Executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
  • 10.7. Rhythm Pharmaceuticals
    • 10.7.1. Company overview
    • 10.7.2. Key Executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
    • 10.7.6. Business performance
    • 10.7.7. Key strategic moves and developments
  • 10.8. Novo Nordisk A/S
    • 10.8.1. Company overview
    • 10.8.2. Key Executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Business performance
    • 10.8.7. Key strategic moves and developments
  • 10.9. GlaxoSmithKline plc
    • 10.9.1. Company overview
    • 10.9.2. Key Executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
  • 10.10. Boehringer Ingelheim International GmbH
    • 10.10.1. Company overview
    • 10.10.2. Key Executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance
    • 10.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 02. ANTI-OBESITY DRUGS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. ANTI-OBESITY DRUGS MARKET FOR OVER THE COUNTER DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 05. ANTI-OBESITY DRUGS MARKET FOR CENTRALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. ANTI-OBESITY DRUGS MARKET FOR PERIPHERALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 08. ANTI-OBESITY DRUGS MARKET FOR ORAL ROUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. ANTI-OBESITY DRUGS MARKET FOR SUBCUTANEOUS ROUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 11. ANTI-OBESITY DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. ANTI-OBESITY DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. ANTI-OBESITY DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. ANTI-OBESITY DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 20. U.S. ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 22. U.S. ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 23. U.S. ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. CANADA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 26. CANADA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 27. CANADA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. UK ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 46. UK ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 47. UK ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. UK ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. ITALY ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ITALY ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 51. ITALY ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 52. ITALY ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 58. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 59. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 62. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 63. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 66. JAPAN ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 67. JAPAN ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 68. JAPAN ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 69. JAPAN ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. CHINA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 71. CHINA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 72. CHINA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. CHINA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 75. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 76. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. INDIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 79. INDIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 80. INDIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 81. INDIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 87. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 88. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 89. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 90. LAMEA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 91. LAMEA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 92. LAMEA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 93. LAMEA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 94. LAMEA ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 95. BRAZIL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 96. BRAZIL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 97. BRAZIL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 98. BRAZIL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 100. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 101. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 102. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 104. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 105. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 106. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 107. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 108. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 109. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 110. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 111. CURRAX PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 112. CURRAX PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 113. CURRAX PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 114. CURRAX PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 115. CURRAX PHARMACEUTICALS LLC: KEY STRATERGIES
  • TABLE 116. KVK TECH INC.: KEY EXECUTIVES
  • TABLE 117. KVK TECH INC.: COMPANY SNAPSHOT
  • TABLE 118. KVK TECH INC.: PRODUCT SEGMENTS
  • TABLE 119. KVK TECH INC.: SERVICE SEGMENTS
  • TABLE 120. KVK TECH INC.: PRODUCT PORTFOLIO
  • TABLE 121. GELESIS HOLDINGS, INC.: KEY EXECUTIVES
  • TABLE 122. GELESIS HOLDINGS, INC.: COMPANY SNAPSHOT
  • TABLE 123. GELESIS HOLDINGS, INC.: SERVICE SEGMENTS
  • TABLE 124. GELESIS HOLDINGS, INC.: PRODUCT PORTFOLIO
  • TABLE 125. GELESIS HOLDINGS, INC.: KEY STRATERGIES
  • TABLE 126. VIVUS LLC.: KEY EXECUTIVES
  • TABLE 127. VIVUS LLC.: COMPANY SNAPSHOT
  • TABLE 128. VIVUS LLC.: PRODUCT SEGMENTS
  • TABLE 129. VIVUS LLC.: SERVICE SEGMENTS
  • TABLE 130. VIVUS LLC.: PRODUCT PORTFOLIO
  • TABLE 131. VIVUS LLC.: KEY STRATERGIES
  • TABLE 132. CHEPLAPHARM ARZNEIMITTEL GMBH: KEY EXECUTIVES
  • TABLE 133. CHEPLAPHARM ARZNEIMITTEL GMBH: COMPANY SNAPSHOT
  • TABLE 134. CHEPLAPHARM ARZNEIMITTEL GMBH: SERVICE SEGMENTS
  • TABLE 135. CHEPLAPHARM ARZNEIMITTEL GMBH: PRODUCT PORTFOLIO
  • TABLE 136. PFIZER INC.: KEY EXECUTIVES
  • TABLE 137. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 138. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 139. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 140. RHYTHM PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 141. RHYTHM PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 142. RHYTHM PHARMACEUTICALS: SERVICE SEGMENTS
  • TABLE 143. RHYTHM PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 144. RHYTHM PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 145. NOVO NORDISK A/S: KEY EXECUTIVES
  • TABLE 146. NOVO NORDISK A/S: COMPANY SNAPSHOT
  • TABLE 147. NOVO NORDISK A/S: PRODUCT SEGMENTS
  • TABLE 148. NOVO NORDISK A/S: PRODUCT PORTFOLIO
  • TABLE 149. NOVO NORDISK A/S: KEY STRATERGIES
  • TABLE 150. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 151. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 152. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 153. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 154. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 155. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 156. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
  • TABLE 157. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 158. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. ANTI-OBESITY DRUGS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF ANTI-OBESITY DRUGS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN ANTI-OBESITY DRUGS MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALANTI-OBESITY DRUGS MARKET
  • FIGURE 10. ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR OVER THE COUNTER DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR CENTRALLY ACTING ANTI-OBESITY DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR PERIPHERALLY ACTING ANTI-OBESITY DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR ORAL ROUTE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR SUBCUTANEOUS ROUTE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF ANTI-OBESITY DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. ANTI-OBESITY DRUGS MARKET BY REGION, 2022
  • FIGURE 24. U.S. ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. CHINA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. AUSTRALIA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. INDIA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: ANTI-OBESITY DRUGS MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2022
  • FIGURE 50. GELESIS HOLDINGS, INC.: NET REVENUE, 2020-2021 ($MILLION)
  • FIGURE 51. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. RHYTHM PHARMACEUTICALS: NET REVENUE, 2021-2022 ($MILLION)
  • FIGURE 55. NOVO NORDISK A/S: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. NOVO NORDISK A/S: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. NOVO NORDISK A/S: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 62. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 63. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2021 (%)